EcoDrugPlus

Dopamine Receptor D4a

Ensembl ID : ENSTNIG00000006556
Gene Symbol: DRD4A
2 Cross references
164 Possible Orthologues:

Dopamine Receptor D4a

Ensembl ID : ENSTNIG00000008439
Gene Symbol: DRD4A
3 Cross references
164 Possible Orthologues:

Dopamine Receptor D4b

Ensembl ID : ENSTNIG00000002252
Gene Symbol: DRD4B
2 Cross references
180 Possible Orthologues:

Dopamine Receptor D5

Ensembl ID : ENSTNIG00000011106
Gene Symbol: DRD5
3 Cross references
147 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSTNIG00000002106
Gene Symbol: ENPP2
2 Cross references
225 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSTNIG00000005380
Gene Symbol: ENPP2
3 Cross references
225 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSTNIG00000016662
Gene Symbol: EGLN1
2 Cross references
220 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSTNIG00000007758
Gene Symbol: EGLN2
2 Cross references
185 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 3

Ensembl ID : ENSTNIG00000002846
Gene Symbol: EGLN3
2 Cross references
198 Possible Orthologues:

Endothelial Pas Domain Protein 1b

Ensembl ID : ENSTNIG00000009866
Gene Symbol: EPAS1B
2 Cross references
210 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSTNIG00000004013
Gene Symbol: ECE1
2 Cross references
230 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSTNIG00000017728
Gene Symbol: EDNRAA
2 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).